Problem

Merge Labs is addressing the core limitations of today’s brain-computer interfaces (BCIs): they generally depend on electrodes and, in many cases, surgery, while providing limited brain coverage and bandwidth. Signals can also be partial or noisy, making it difficult for computers to reliably infer a person’s intent. The human and economic stakes are clearest in restoring capabilities lost through injury or disease, while the longer-term opportunity is more natural communication with computers and AI.

The company’s initial “killer” use case is assistive technology for patients with neurological injury or disease—enabling them to interact with computers or regain lost abilities through brain signals. Over time, Merge Labs aims to extend the same technology beyond medical restoration toward broader improvements in human agency, creativity, and capability.

Product / Service

Merge Labs is currently a research lab developing a new generation of high-bandwidth, less-invasive BCIs. Its proposed approach combines biology, devices, and AI; it is exploring molecular interfaces with neurons rather than conventional electrodes, deep-reaching modalities such as ultrasound, and systems that avoid implanting hardware into brain tissue. The intended benefit is substantially greater brain coverage and information bandwidth in a form factor that is safer and more accessible.

AI is central both to the product and to the research process. Merge Labs plans to develop an AI operating layer that can interpret noisy brain activity, learn an individual’s patterns, and translate intent into reliable computer interaction, while using AI models to accelerate neuroscience, bioengineering, and device development. The company says it is starting as a research organization, with the long-term objective of turning the work into products that people use.

Market

Merge Labs competes in the emerging brain-computer-interface and neurotechnology market, at the intersection of medical devices, consumer hardware, neuroscience, and AI. Its most visible competitor is Neuralink: both are pursuing brain-computer interfaces, but Merge Labs is positioning itself around a less-invasive, ultrasound- and molecule-based approach rather than Neuralink’s electrode-based implants. The technology remains early-stage, and independent reporting describes the science as not yet mature.

The company emerged publicly in January 2026 with approximately $252 million in reported seed funding, including investment and planned scientific collaboration from OpenAI; reporting also placed its initial valuation near $850 million. That is substantial financing traction, but the available evidence describes Merge Labs as a long-term research organization rather than a commercial product company and does not document customers, revenue, or a launched product, so it is best characterized as pre-commercial. The supplied mergelabs.com domain did not resolve to the company in the research; Merge Labs’ own public launch page is at merge.io.